High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 62-69

  Lau, Wei Ling ^a   Linnes, Michael ^b   Chu, Emily Y ^a   Foster, Brian L ^c   Bartley, Bryan A ^d   Somerman, Martha J ^c   Giachelli, Cecilia M ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d University of Washington   (United States)

Author keywords

chronic kidney disease mineral bone disorder; high turnover renal osteodystrophy; phosphate; vascular calcification

Indexed keywords

ALKALINE PHOSPHATASE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CALCIFICATION; ARTERY MEDIA; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; CONTROLLED STUDY; CORTICAL BONE; FEMALE; LONG BONE; METABOLIC BONE DISEASE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DISEASES; FEMALE; MICE; MICE, INBRED DBA; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VASCULAR CALCIFICATION;

EID: 84872244680     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs333     Document Type: Article

References (52)

1. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving klobal outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
2. Block G, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In: Olgaard K (ed). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. New York: National Kidney Foundation, 2006, pp. 77-92.
3. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
4. Shroff R, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757.
5. González EA, Lund RJ, Martin KJ et al. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 2002; 61: 1322-1331.
6. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359-369.
7. Hendy GN, Hruska KA, Mathew S et al. New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int 2006; 69: 218-223.
8. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 836-843.
9. Stehman-Breen C. Osteoporosis and chronic kidney disease. Semin Nephrol 2004; 24: 78-81.
10. Hruska KA, Choi ET, Memon I et al. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKDMBD). Pediatr Nephrol 2010; 25: 769-778.
11. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
12. Lau WL. Direct effects of phosphate on vascular cell function. In: Pai A, Giachelli CM (eds). Advances in Chronic Kidney Disease, 2011.
13. Block G, Hulbert-Shearon T, Levin N et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
14. Young E, Albert J, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187.
15. Chertow G, Burke S, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
16. Block G, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
17. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
18. Giachelli C. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897.
19. El-Abbadi MM, Pai AS, Leaf EM et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
20. Pai A, Leaf EM, El-Abbadi M et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 2011; 178: 764-773.
21. Toussaint ND, Lau KK, Strauss BJ et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586-593.
22. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105.
23. Gagnon R, Gallimore B. Characterization of a mouse model of chronic uremia. Urol Res 1988; 16: 119-126.
24. Wada T, McKee M, Steitz S et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178.
25. Lee MM, Chu EY, El-Abbadi MM et al. Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol 2010; 81: 300-309.
26. Ivandic BT, Qiao JH, Machleder D et al. A locus on chromosome 7 determines myocardial cell necrosis and calcification (dystrophic cardiac calcinosis) in mice. Proc Natl Acad Sci USA 1996; 93: 5483-5488.
27. Ivandic BT, Utz HF, Kaczmarek PM et al. New dyscalc loci for myocardial cell necrosis and calcification (dystrophic cardiac calcinosis) in mice. Physiol Genomics 2001; 6: 137-144.
28. Eaton GJ, Custer RP, Johnson FN et al. Dystrophic cardiac calcinosis in mice: genetic, hormonal, and dietary influences. Am J Pathol 1978; 90: 173-186.
29. Nikolov IG, Joki N, Nguyen-Khoa T et al. Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein Edeficient mice with chronic renal failure. Bone 2010; 47: 156-163.
30. Moe SM, Chen NX, Seifert MF et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009; 75: 176-184.
31. Katsumata K, Kusano K, Hirata M et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
32. Damment S, Secker R, Shen V et al. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 2011; 26: 1803-1812.
33. Westenfeld R, Schäfer C, Smeets R et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007; 22: 1537-1546.
34. De Schutter TM, Neven E, Persy VP et al. Vascular calcification is associated with cortical bone loss in chronic renal failure rats with and without ovariectomy: the calcification paradox. Am J Nephrol 2011; 34: 356-366.
35. Bacic D, Lehir M, Biber J et al. The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int 2006; 69: 495-503.
36. Segawa H, Yamanaka S, Onitsuka A et al. Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol Renal Physiol 2007; 292: F395-F403.
37. Saji F, Shigematsu T, Sakaguchi T et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299: F1212-F1217.
38. Huang JC, Sakata T, Pfleger LL et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004; 19: 235-244.
39. Lotinun S, Sibonga JD, Turner RT. Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 2005; 146: 4074-4081.
40. Bleyer AJ, Burkart J, Piazza M et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46: 464-469.
41. Price PA, June HH, Buckley JR et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616.
42. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824.
43. Lomashvili KA, Monier-Faugere MC, Wang X et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-625.
44. Di Bartolo BA, Schoppet M, Mattar MZ et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 2011; 91: 537-545.
45. van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. Lab Anim 1998; 32: 483-491.
46. Moe S, Chen N. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216.
47. Akintoye SO, Lam T, Shi S et al. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 2006; 38: 758-768.
48. Yamaza T, Ren G, Akiyama K et al. Mouse mandible contains distinctive mesenchymal stem cells. J Dent Res 2011; 90: 317-324.
49. Sodek J, McKee MD. Molecular and cellular biology of alveolar bone. Periodontol 2000 2000; 24: 99-126.
50. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010; 25: 98-105.
51. Manske SL, Liu-Ambrose T, Cooper DM et al. Cortical and trabecular bone in the femoral neck both contribute to proximal femur failure load prediction. Osteoporos Int 2009; 20: 445-453.
52. Holzer G, von Skrbensky G, Holzer LA et al. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res 2009; 24: 468-474.